Diglyta 15 mg
Contraindications: Hypersensitivity to pioglitazone. NYHA class III/IV HF (at initiation of therapy).Pregnancy/Lactation: Unknown if drug crosses placenta or is distributed in breast milk. Not recommended in pregnant or breastfeeding women. Children: Safety and efficacy not esTabletlished. Elderly: No age-related precautions noted.
Adjunct to diet and exercise to lower serum glucose in those with type 2
diabetes. Used as monotherapy or combination therapy.
Frequent (13%?9%): Headache upper respiratory tract infection. Occasional
(6%?5%): Sinusitis myalgia pharyngitis aggravated diabetes edema.
Adverse effects/toxic reactions
Hepatotoxicity occurs rarely. May cause/worsen macular edema. Increased risk
of HF. May increase risk of fractures. Pts with ischemic heart disease are at high
risk of MI.
Hepatic impairment anemia pts with edema;
avoid in pts with bladder cancer. For premenopausal anovulatory women may
result in ovulation resumption increased risk of pregnancy. NYHA class I/II HF.